Arca
Skip to content
Tools
Tools

REVERSE, TRANSCRIPTASE: Reverse transcriptase

Protein in Human immunodeficiency virus 2 that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on REVERSE, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved0

    Phase 33

    • Islatravir
    • Apricitabine
    • RO-0622

    Phase 22

    • Censavudine
    • Tenofovir exalidex

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Reverse transcriptase inhibitor.
      IslatravirPhase 3Merck & Co. (MSD)Small moleculeInhibitor12
      ApricitabinePhase 3AvexaSmall moleculeInhibitor0
      RO-0622Phase 3Shanghai Henlius BiotechSmall moleculeInhibitor0
      CensavudinePhase 2Bristol-Myers SquibbSmall moleculeInhibitor0
      Tenofovir exalidexPhase 2ContraVir Pharmaceuticals, Inc.Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIVIslatravirPhase 2Not yet recruitingThe University of Texas Health Science Center, HoustonOct 13, 2026
      DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgIslatravirPhase 2Not yet recruitingMerck Sharp & Dohme LLCOct 7, 2026
      A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)IslatravirPhase 2 / Phase 3RecruitingMerck Sharp & Dohme LLCDec 5, 2025
      A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)IslatravirPhase 2Active, not recruitingMerck Sharp & Dohme LLCMar 24, 2025
      Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1IslatravirPhase 3Active, not recruitingGilead SciencesOct 8, 2024
      Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1IslatravirPhase 3Active, not recruitingGilead SciencesOct 8, 2024
      A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)IslatravirPhase 3Active, not recruitingMerck Sharp & Dohme LLCMar 13, 2023
      DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)IslatravirPhase 3Active, not recruitingMerck Sharp & Dohme LLCJan 30, 2023

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1681630, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.